[go: up one dir, main page]

CA2478145A1 - Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer - Google Patents

Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer Download PDF

Info

Publication number
CA2478145A1
CA2478145A1 CA002478145A CA2478145A CA2478145A1 CA 2478145 A1 CA2478145 A1 CA 2478145A1 CA 002478145 A CA002478145 A CA 002478145A CA 2478145 A CA2478145 A CA 2478145A CA 2478145 A1 CA2478145 A1 CA 2478145A1
Authority
CA
Canada
Prior art keywords
nitric oxide
cancer
cells
tumor
mimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478145A
Other languages
English (en)
Inventor
Charles H. Graham
Lynne-Marie Postovit
Michael A. Adams
Jeremy P. W. Heaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478145A1 publication Critical patent/CA2478145A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés et des formulations permettant d'inhiber, de traiter et de prévenir un phénotype cellulaire malin, une cellule, une tumeur et/ou une maladie. L'administration de substances mimétiques d'oxyde nitrique, en faibles doses, suffit pour accroître, restaurer ou maintenir la signalisation induite par l'oxyde nitrique dans des cellules, de manière que ces phénotypes cellulaires malins, ces cellules, ces tumeurs et/ou ces maladies soient inhibés ou prévenus. Ces procédés et formulations sont particulièrement utiles pour le traitement et la prévention du cancer chez des animaux.
CA002478145A 2002-03-06 2003-03-06 Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer Abandoned CA2478145A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36296902P 2002-03-06 2002-03-06
US60/362,969 2002-03-06
US36262002P 2002-03-07 2002-03-07
US60/362,620 2002-03-07
PCT/CA2003/000313 WO2003074082A1 (fr) 2002-03-06 2003-03-06 Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2478145A1 true CA2478145A1 (fr) 2003-09-12

Family

ID=27791719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478145A Abandoned CA2478145A1 (fr) 2002-03-06 2003-03-06 Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer

Country Status (5)

Country Link
EP (1) EP1492567A1 (fr)
JP (1) JP2005527510A (fr)
AU (1) AU2003208228A1 (fr)
CA (1) CA2478145A1 (fr)
WO (1) WO2003074082A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
WO2005120493A1 (fr) * 2004-06-10 2005-12-22 Tohoku University Promoteur de l'effet anticancereux
DE602004022463D1 (de) * 2004-08-19 2009-09-17 Switch Biotech Llc Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen
CA2619779C (fr) * 2004-08-19 2013-03-12 Switch Biotech Ag Utilisation d'un inhibiteur de la pde5 pour le traitement et la prevention de troubles caracterises par une hypopigmentation
AU2012203798B2 (en) * 2005-08-12 2013-11-07 Northrop Grumman Systems Corporation O-nitro compounds, pharmaceutical compositons thereof and uses thereof
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
EP2237788A4 (fr) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc Composés permettant d'obtenir du nitrite et de l'oxyde nitrique aérosolisés et leurs utilisations
JP5467259B2 (ja) * 2008-03-13 2014-04-09 国立大学法人 千葉大学 シスプラチン効果増強剤及び抗癌剤キット
WO2009137071A1 (fr) * 2008-05-09 2009-11-12 Duke University Traitement de maladies fondé sur la découverte du fait que la thiorédoxine induit la libération d’oxyde nitrique dans les cellules
CA2823066A1 (fr) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions contenant des peptides natriuretiques et leurs methodes d'utilisation
CN107261119A (zh) * 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 恶性肿瘤转移抑制用药物
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
AU2015243537B2 (en) * 2014-04-08 2020-10-22 The Methodist Hospital INOS-inhibitory compositions and their use as breast cancer therapeutics
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (fr) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Traitement de crise avec une phosphatase alcaline recombinee
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (fr) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp)
WO2017074466A1 (fr) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
EP3426286A4 (fr) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez l'enfant
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3436020A4 (fr) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (fr) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa le traitement de la trachéobronchomalacie
CA3057502A1 (fr) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN114869894A (zh) * 2022-05-10 2022-08-09 福州大学 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV11542B (en) * 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
WO1999003462A1 (fr) * 1997-07-14 1999-01-28 Brigham And Women's Hospital MODIFICATION DE L'ACTIVITE DU MONOXYDE D'AZOTE POUR LE TRAITEMENT DE PATHOLOGIES INDUITES PAR LE Fas
WO2001054680A2 (fr) * 2000-01-26 2001-08-02 Cedars-Sinai Medical Center Procede utilisant l'activation des canaux potassiques pour l'apport d'un medicament jusqu'a une region anormale du cerveau et/ou jusqu'a une tumeur maligne
US20010038832A1 (en) * 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
US6946484B2 (en) * 2000-04-26 2005-09-20 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Also Published As

Publication number Publication date
EP1492567A1 (fr) 2005-01-05
JP2005527510A (ja) 2005-09-15
AU2003208228A1 (en) 2003-09-16
WO2003074082A1 (fr) 2003-09-12

Similar Documents

Publication Publication Date Title
US8168232B2 (en) Formulations and methods of using nitric oxide mimetics in cancer treatment
CA2478145A1 (fr) Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer
US6946484B2 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU2001250221A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6689787B1 (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
KR102462177B1 (ko) Ｍｄｍ２ 억제제의 간헐적 투여
EP1502604A1 (fr) Utilisation de substances mimetiques de l'oxide nitrique dans le traitement du cancer
AU2016271527A1 (en) PAC-1 combination therapy
KR100858946B1 (ko) 초기 유방암을 가진 폐경후 여성의 치료를 위한아나스트로졸의 용도
AU2013208649B2 (en) Combination therapy for the treatment of cancer
US20220323474A1 (en) Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease
EP2432480B1 (fr) Compositions et procédés pour traiter une arthrite inflammatoire
JP2022547702A (ja) 胆管癌の処置のためのパノビノスタットを含む併用療法
WO2021048419A1 (fr) Polythérapies comprenant du tramétinib pour le traitement du cholangiocarcinome
RU2776995C2 (ru) Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью
TW202128213A (zh) 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途
JP2002524481A5 (fr)
WO2011056663A1 (fr) Procédé de traitement du cancer en utilisant une combinaison d'un agent alkylant bifonctionnel et d'inhibiteurs de la réparation de l'adn
JP2010507628A (ja) 骨ガンの処置又は予防のためのｍｔｋｉ１の使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead